Remembering Nora Ephron — and Understanding Acute Myeloid Leukemia

What was said, and what had not been

On June 27, 2012, the Leukemia & Lymphoma Society issued a statement on the death of the writer and filmmaker Nora Ephron. It named her illness precisely. She died "from acute myelogenous leukemia (AML)." The society added that she "had been battling myelodysplastic syndrome (MDS), which then progressed to AML."

Almost nobody outside her family knew. She had kept the illness private while she went on working, and the diagnosis surprised many of her friends.

That is her whole public medical record. Keeping a diagnosis private is a legitimate choice, and this article treats it as one. What is worth explaining is the sequence the society described. MDS turning into AML is a specific path, and many families meet it without warning.

Two diagnoses on one continuum

Bone marrow makes blood. In MDS, it makes cells that never mature properly. They die in the marrow, or soon after they reach the bloodstream. The result is a shortage of red cells, white cells, platelets, or all three. Doctors call each shortage a cytopenia.

NCI reports slightly more than 10,000 people diagnosed with MDS in the United States each year. That is a rate of roughly 4.4 to 4.6 per 100,000, and the median age is around 70. MDS can arise on its own. It can also develop after chemotherapy or radiation given for a different cancer.

The society called MDS a frequent precursor to AML. It described AML as a fast-moving blood cancer, caused by changes a marrow cell acquires in its DNA.

What changes when MDS becomes AML

The line between the two is a number. Immature marrow cells are called blasts. NCI states that by convention MDS is reclassified as acute myeloid leukemia when blasts in the blood or bone marrow reach or exceed 20 percent.

The World Health Organization gives this situation its own name: AML with myelodysplasia-related features. The label exists because it behaves differently from leukemia that appears out of nowhere.

NCI lists a history of MDS, or another preceding blood disorder, among the adverse prognostic factors in AML. Leukemia that grew out of a damaged marrow is harder to treat than leukemia in a marrow that was healthy.

NCI also makes a point that gets lost here. Many people with MDS die of the complications of low blood counts, meaning infection or bleeding. They never reach that 20 percent mark. The shortage itself is dangerous.

What either one feels like

The symptoms overlap almost completely, because both diseases starve the body of working blood cells.

For MDS, NCI lists shortness of breath, weakness or tiredness, skin paler than usual, and easy bruising or bleeding. It also lists petechiae, which are flat pinpoint spots under the skin caused by bleeding.

For AML, NCI lists weakness, fever, infection, pallor, and bleeding. The difference is pace. NCI notes that the symptoms of acute leukemia usually arise over four to six weeks before diagnosis. MDS can smolder for years.

When to get checked

The route into both diseases is a blood count, not a scan. Ask for one, and ask for it to be repeated, if:

• Breathlessness or exhaustion has been building over weeks with no explanation.
• You bruise from contact that would not have marked you last year.
• Pinpoint red or purple spots appear on the skin, often on the lower legs.
• Bleeding gums, frequent nosebleeds, or cuts that keep oozing.
• Fevers or infections keep returning, or take far longer than usual to clear.
• A previous blood test came back abnormal and was never followed up.

Two findings need same-day attention. NCI lists a white cell count above 100,000 per cubic millimeter as an adverse feature in AML. It needs urgent care. So does a fever in anyone known to have a low neutrophil count. That is an emergency, however well the person looks.

There is no screening program for either disease. NCI has no evidence-based screening or prevention summary for leukemia, so nearly every case is found through a blood test ordered for something else.

Confirming the diagnosis

A complete blood count with differential usually raises the question, and a blood smear may show blasts directly.

The answer comes from a bone marrow aspiration and biopsy, taken by needle from the hipbone or breastbone. Flow cytometry then reads the proteins on the cell surfaces. NCI calls this the primary tool for separating AML from chronic myeloid leukemia and acute lymphocytic leukemia. That distinction has, in its words, vital therapeutic implications.

Chromosome and gene testing follows. Labs look at NPM1, FLT3, CEBPA, RUNX1, and others. NCI states that these analyses provide the strongest prognostic information available.

Treatment, and where the history weighs

AML treatment runs in two phases. Remission induction uses cytarabine with an anthracycline drug. The goal is to clear leukemia cells and restore normal counts. Consolidation follows, often with high-dose cytarabine. It targets cells that survived but cannot be detected. A stem cell transplant is considered for people with adverse features.

Roughly 60 to 70 percent of adults reach complete remission after induction. Age shifts that sharply. NCI reports expected remission rates above 65 percent in adults under 60. Older patients face higher illness and death rates during induction, and shorter remissions once achieved.

The anthracycline drugs carry a specific long-term cost worth knowing. NCI cites doxorubicin-related congestive heart failure in about 5 percent of patients at a lifetime cumulative dose of 400 mg per square meter, rising to 26 percent at 550 mg per square meter.

Reading the numbers

The American Cancer Society's projection for 2026 is 22,720 new AML cases and 11,500 deaths in the United States, replacing the 22,010 and 11,090 it gave for 2025 that NCI's PDQ summary reprints; PDQ gives the median age at diagnosis as 69. SEER's own measurement, on people diagnosed from 2016 through 2022, is that 33.4 percent were alive five years after diagnosis.

That single percentage covers dozens of genetically distinct diseases grouped under one name. It spans every age and every level of fitness. It is a summary of a population, and it describes no individual. It did not describe Nora Ephron, and it does not describe any reader.

Sources

• https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
• https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
• https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq
• https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq
• https://www.prnewswire.com/news-releases/the-leukemia--lymphoma-society-mourns-the-loss-of-author-and-filmmaker-nora-ephron-160547005.html
• https://www.cancer.org/research/cancer-facts-statistics.html